So What is CAR T-cell Therapy?
Our bodies have a built-in defense system. One part of it is a group of cells called T cells. Their job is to move through the body, looking for cells that don’t belong. When they find one, they attach and destroy it.
With B-cell Acute Lymphoblastic Leukemia, this system breaks down. The leukemia involves B cells—cells that normally help fight infection, but are now growing recklessly. Because the cancer is coming from inside the immune system itself, the T cells don’t always recognize it as dangerous. They pass it by.
CAR T therapy is a way of retraining the body’s own T cells to do their job differently.
Doctors collect a large number of T cells from the patient and send them to a lab. This process is called Apheresis. You can read about our story with that here. At the lab, the cells are changed so they can recognize a specific marker on B cells without relying on the usual immune signals—the ones cancer often learns how to evade.
Once those T cells are given back to the patient, they go looking for anything with that marker and destroy it. This includes leukemia cells—but also healthy B cells. That’s part of the trade-off which we will discuss below.
CAR T therapy can be incredibly effective, especially for kids whose leukemia has come back. Many patients reach remission after treatment. But it isn’t a permanent fix for everyone. Sometimes the CAR T cells don’t last as long as hoped, and over time, B cells—healthy or leukemic—can return. Researchers are still working to understand why some children respond to CAR T therapy and others don’t.
What is the downside of CAR T-cell Therapy?
After the leukemia cells are destroyed, the CAR T cells don’t automatically stand down. They stay active, continuing to look for the marker they were trained to recognize.
The challenge is that this marker is found not only on leukemia cells, but also on healthy B cells. CAR T cells can’t tell the difference. They are designed to eliminate all cells that carry that marker. As a result, patients are left without any B cells, healthy or leukemic.
This is expected—and even used as a sign that the therapy is still working. Doctors monitor B-cell levels after treatment. If B cells remain absent, it suggests the CAR T cells are still active and doing their job. This ongoing absence of B cells is called B-cell aplasia. This is the measure you pray for.
However, B cells play an important role in fighting infection and so with them absent, patients need added immune support. This comes in the form of IVIG (intravenous immunoglobulin), an infusion that replaces some of the immune protection normally provided by B cells. Some patients receive IVIG monthly or every few months for years after CAR T therapy. While it is effective, it can have side effects and means ongoing dependence on external immune support.
CAR T therapy is still a relatively new treatment, and the science continues to evolve. Researchers are actively studying ways to turn CAR T cells “off” once they’ve done their job, but that option is not yet available.
Another important consideration is something called cytokine release syndrome, sometimes referred to as a cytokine storm. As CAR T cells attack and kill leukemia cells, the body can release a surge of inflammatory signals. Symptoms range from mild—such as fever, headache, or nausea—to more serious, including confusion or stroke-like symptoms. Most patients require hospitalization, and some need care in the ICU. As this therapy has become more common, doctors have also become much better at recognizing and treating these reactions.
In Beaudin’s case, because his disease burden is currently low, the expectation is that any reaction would fall on the milder end of the spectrum. Still, nothing can be guaranteed. For that reason, families are required to stay within 20 minutes of the hospital for 3 to 22 days after infusion so care is immediately available if needed.
CAR T-cell Therapy as a Path Forward
CAR T-cell therapy is part of a growing area of cancer treatment called immunotherapy. Rather than relying only on chemotherapy—which affects healthy and cancerous cells alike—immunotherapy is based on the idea that the body can fight cancer when given the right tools.
Because this approach is still relatively new, it doesn’t yet have the decades of data that chemotherapy does. Even so, early results have been encouraging, with many patients responding well and, in some cases, experiencing fewer long-term side effects.
New treatments are usually offered first to patients with the fewest remaining options. When standard chemotherapy offers a high chance of remission, most families understandably choose that path. As a result, many children who receive CAR T therapy today are those who have relapsed multiple times, reached chemotherapy limits, or whose leukemia no longer responds to chemo. These are often very sick children with aggressive disease, which shapes how the statistics should be understood.
The study we are hoping to join asks a different question:
What if we didn’t wait until a child was out of options?
What if, after a first relapse—once it’s clear standard chemotherapy hasn’t worked—we used CAR T therapy earlier?
Early data suggest this approach may lead to better outcomes, but large, long-term studies are still needed before treatment guidelines can change. This study exists to begin collecting that data and to explore whether there is another way to treat relapsed leukemia without years of repeated chemotherapy or radiation, both of which carry lasting risks.
This science is still evolving, and my understanding will continue to grow as we learn more. For now, this is my best attempt to explain it—one parent’s effort to understand new science well enough to make the best decision possible.
Links, Videos, Articles on CAR T-cell Therapy
CAR T-Cell Therapy: How Does It Work?
An overview of how and why T cells can be used for CAR therapy.
For Kids
How CAR T-Cell Therapy Works: An Animation for Kids
A very simple and short, kid-friendly explanation of T-cell therapy.
How Do People Catch a Cold? 🤒 Ask the StoryBots FULL EPISODE | Netflix
This is a great option for kids to have a little better understanding of how the immune system functions. It doesn’t speak to cancer, but it does introduce T cells and how our body works to fight bad cells. It can be watched on YouTube (linked above) or Netflix.
Questions?
I’d love to know what questions you have about CAR T-cell therapy or Beaudin’s treatment specifically, please comment below!
Leave a Reply